Biocon’s Pertuzumab has received a positive EMA CHMP recommendation, becoming the first biosimilar to clear the agency’s new tailored clinical development approach for HER2-positive breast cancer
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.